anaemia
Market Access/ News/ News/ News/ R&D
GSK shelves arthritis blockbuster hope otilimab after lacklustre data
Phil Taylor
anaemia, chronic kidney disease, daprodustat, GlaxoSmithKline, MorphoSys, otilimab, Rheumatoid arthritis
0 Comment
GSK’s daprodustat will have to face FDA advisory committee
Phil Taylor
anaemia, chronic kidney disease, daprodustat, fda, GlaxoSmithKline, nephrology, regulatory
0 Comment
Market Access/ News/ News/ News/ Oncology
GSK gets June 2023 FDA decision date for momelotinib
Phil Taylor
anaemia, GlaxoSmithKline, momelotinib, myelofibrosis, regulatory, Sierra Oncology
0 Comment
NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease
Phil Taylor
anaemia, Astellas, chronic kidney disease, Evrenzo, HEOR, NHS, NICE
0 Comment
GSK goes for gold as FDA starts review of daprodustat
Phil Taylor
Akebia Therapeutics, anaemia, AstraZeneca, chronic kidney disease, daprodustat, FibroGen, GlaxoSmithKline, roxadustat, vadadustat
0 Comment
After FDA snub, EMA backs FibroGen, Astellas’ roxadustat
Phil Taylor
Akebia Therapeutics, anaemia, Astellas, chronic kidney disease, daprodustat, EU, FibroGen, GlaxoSmithKline, Haematology, regulatory approval, roxadustat, vadadustat
0 Comment
GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival
Richard Staines
anaemia, Astellas, AstraZeneca, chronic kidney disease, Duvroq, FibroGen, GlaxoSmithKline, Kyowa Kirin
0 Comment
Celgene scores FDA okay for thalassaemia drug Reblozyl
Phil Taylor
Acceleron, anaemia, beta thalassaemia, Celgene, FDA approval
0 Comment